Shares of Iovance Biotherapeutics Inc. (IOVA) have gained more than 60% over the last 4 trading days, thanks to favorable regulatory developments concerning its one-time tumor-infiltrating lymphocyte therapy, Lifileucel.
Lifileucel was granted accelerated approval by the FDA for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor on Feb.16, 2024.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com